297 related articles for article (PubMed ID: 22870914)
1. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
2. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
[TBL] [Abstract][Full Text] [Related]
3. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M
Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349
[TBL] [Abstract][Full Text] [Related]
4. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
5. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism.
Groll M; Schellenberg B; Bachmann AS; Archer CR; Huber R; Powell TK; Lindow S; Kaiser M; Dudler R
Nature; 2008 Apr; 452(7188):755-8. PubMed ID: 18401409
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
7. Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines.
Anshu A; Thomas S; Agarwal P; Ibarra-Rivera TR; Pirrung MC; Schönthal AH
Biochem Pharmacol; 2011 Sep; 82(6):600-9. PubMed ID: 21736873
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
9. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines.
Clerc J; Florea BI; Kraus M; Groll M; Huber R; Bachmann AS; Dudler R; Driessen C; Overkleeft HS; Kaiser M
Chembiochem; 2009 Nov; 10(16):2638-43. PubMed ID: 19746508
[TBL] [Abstract][Full Text] [Related]
10. Heterologous expression of a Photorhabdus luminescens syrbactin-like gene cluster results in production of the potent proteasome inhibitor glidobactin A.
Dudnik A; Bigler L; Dudler R
Microbiol Res; 2013 Feb; 168(2):73-6. PubMed ID: 23079192
[TBL] [Abstract][Full Text] [Related]
11. Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition.
Clerc J; Groll M; Illich DJ; Bachmann AS; Huber R; Schellenberg B; Dudler R; Kaiser M
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6507-12. PubMed ID: 19359491
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
13. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study of syringolin A as a potential anticancer agent.
Chiba T; Matsuda A; Ichikawa S
Bioorg Med Chem Lett; 2015 Nov; 25(21):4872-4877. PubMed ID: 26231162
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
16. Proteasome activity imaging and profiling characterizes bacterial effector syringolin A.
Kolodziejek I; Misas-Villamil JC; Kaschani F; Clerc J; Gu C; Krahn D; Niessen S; Verdoes M; Willems LI; Overkleeft HS; Kaiser M; van der Hoorn RA
Plant Physiol; 2011 Jan; 155(1):477-89. PubMed ID: 21045122
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
[TBL] [Abstract][Full Text] [Related]
18. Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
Kawamura S; Unno Y; List A; Mizuno A; Tanaka M; Sasaki T; Arisawa M; Asai A; Groll M; Shuto S
J Med Chem; 2013 May; 56(9):3689-700. PubMed ID: 23547757
[TBL] [Abstract][Full Text] [Related]
19. Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA).
Wei D; Tang M; Zhan CG
Org Biomol Chem; 2015 Jun; 13(24):6857-65. PubMed ID: 26018983
[TBL] [Abstract][Full Text] [Related]
20. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
